Overview
A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides
Status:
Completed
Completed
Trial end date:
2006-11-01
2006-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To assess the safety and efficacy of the fixed combination torcetrapib/atorvastatin in subjects with Fredrickson Type IV Hypertriglyceridemia.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
PfizerTreatments:
Atorvastatin
Atorvastatin Calcium
Torcetrapib
Criteria
Inclusion Criteria:- Diagnosis of Fredrickson Type IV Hypertriglyceridemia
Exclusion Criteria:
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor)
therapy other than atorvastatin or other concomitant therapy with known lipid altering
effects on LDL-C and HDL-C including fibrates and nicotinic acid
- Subjects taking any drugs known to be associated with an increased risk of myositis in
combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could affect
subject safety, preclude evaluation of response, or render unlikely that the subject
would complete the study